Andreas Ramming

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5747483/publications.pdf

Version: 2024-02-01

48 papers	2,873 citations	185998 28 h-index	205818 48 g-index
50 all docs	50 docs citations	50 times ranked	5206 citing authors

#	Article	IF	Citations
1	Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy. Rheumatology, 2022, 61, 2999-3009.	0.9	37
2	Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease. Annals of the Rheumatic Diseases, 2022, 81, 1023-1027.	0.5	40
3	Patient's Perception of Digital Symptom Assessment Technologies in Rheumatology: Results From a Multicentre Study. Frontiers in Public Health, 2022, 10, 844669.	1.3	17
4	Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against <scp>SARS</scp>â€“<scp>CoV</scp>â€2 in an Unvaccinated Cohort. Arthritis and Rheumatology, 2022, 74, 783-790.	2.9	9
5	Concise report: a minimal-invasive method to retrieve and identify entheseal tissue from psoriatic arthritis patients. Annals of the Rheumatic Diseases, 2022, 81, 1131-1135.	0.5	6
6	Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease. Annals of the Rheumatic Diseases, 2022, 81, 1400-1408.	0.5	11
7	Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 451-468.	0.5	43
8	Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482098280.	1.4	14
9	Matricellular Protein SPARCL1 Regulates Blood Vessel Integrity and Antagonizes Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1491-1502.	0.9	9
10	Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial. Arthritis Research and Therapy, 2021, 23, 112.	1.6	40
11	SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases, 2021, 80, 1312-1316.	0.5	154
12	The Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases. International Journal of Molecular Sciences, 2021, 22, 7506.	1.8	6
13	TGFÎ² promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy. Nature Communications, 2021, 12, 4404.	5.8	40
14	Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 137-149.	2.9	75
15	Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis. Science Translational Medicine, 2020, 12, .	5.8	26
16	Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Annals of the Rheumatic Diseases, 2020, 79, 1485-1491.	0.5	111
17	Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nature Communications, 2020, 11, 3774.	5.8	78
18	ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure. Frontiers in Immunology, 2020, 11, 691.	2.2	15

#	Article	IF	Citations
19	PGC-1Î± regulates autophagy to promote fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2020, 79, 1227-1233.	0.5	19
20	Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1385-1395.	2.9	13
21	Ethanol consumption inhibits TFH cell responses and the development of autoimmune arthritis. Nature Communications, 2020, 11, 1998.	5.8	48
22	TGF-Î²â€“induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. Journal of Clinical Investigation, 2020, 130, 2347-2363.	3.9	76
23	PU.1 controls fibroblast polarization and tissue fibrosis. Nature, 2019, 566, 344-349.	13.7	121
24	What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis. Annals of the Rheumatic Diseases, 2019, 78, 1220-1225.	0.5	35
25	Acyltransferase skinny hedgehog regulates TGFÎ²-dependent fibroblast activation in SSc. Annals of the Rheumatic Diseases, 2019, 78, 1269-1273.	0.5	16
26	IFN-Î³ drives inflammatory bowel disease pathogenesis through VE-cadherinâ€“directed vascular barrier disruption. Journal of Clinical Investigation, 2019, 129, 4691-4707.	3.9	141
27	Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis. Journal of Immunology, 2018, 200, 1249-1254.	0.4	74
28	Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Annals of the Rheumatic Diseases, 2018, 77, 459-459.	0.5	33
29	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 626-628.	0.5	12
30	The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2018, 77, 150-158.	0.5	51
31	Innate lymphoid cells and fibrotic regulation. Immunology Letters, 2018, 195, 38-44.	1.1	13
32	Group 2 Innate Lymphoid Cells Attenuate Inflammatory Arthritis and Protect from Bone Destruction in Mice. Cell Reports, 2018, 24, 169-180.	2.9	64
33	The tyrosine phosphatase SHP2 controls TGFÎ²-induced STAT3 signaling to regulate fibroblast activation and fibrosis. Nature Communications, 2018, 9, 3259.	5.8	89
34	Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production. Annals of the Rheumatic Diseases, 2018, 77, 1773-1781.	0.5	52
35	Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Annals of the Rheumatic Diseases, 2017, 76, 1133-1141.	0.5	66
36	The transcription factor GLI2 as a downstream mediator of transforming growth factor-Î²-induced fibroblast activation in SSc. Annals of the Rheumatic Diseases, 2017, 76, 756-764.	0.5	53

#	Article	IF	Citations
37	Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2017, 76, 244-251.	0.5	28
38	JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Annals of the Rheumatic Diseases, 2017, 76, 1467-1475.	0.5	41
39	Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nature Communications, 2017, 8, 1130.	5.8	245
40	Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nature Medicine, 2017, 23, 938-944.	15.2	223
41	Updates on animal models of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2016, 1, 266-276.	1.0	14
42	Evidence of innate lymphoid cell redundancy in humans. Nature Immunology, 2016, 17, 1291-1299.	7.0	260
43	Activating transcription factor 3 regulates canonical TGFÎ² signalling in systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 586-592.	0.5	28
44	Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 623-626.	0.5	78
45	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 883-890.	0.5	154
46	From pathogenesis to therapy â€“ Perspective on treatment strategies in fibrotic diseases. Pharmacological Research, 2015, 100, 93-100.	3.1	17
47	Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development. Blood, 2012, 119, 4665-4674.	0.6	66
48	Homotypic T-cell/T-cell interaction induces T-cell activation, proliferation, and differentiation. Human Immunology, 2009, 70, 873-881.	1.2	11